MoonLake Immunotherapeutics
NASDAQ:MLTX
53.71 (USD) • At close September 19, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 Q3 | 2022 Q2 | 2022 Q1 | 2021 Q4 | 2021 Q3 | 2021 Q2 | 2021 Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 0.02 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 0.028 | 0.023 | 0.003 | 0.003 | 0.003 | 0.003 | 0.003 | 0.003 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit
| -0.028 | -0.023 | 0.016 | -0.003 | -0.003 | -0.003 | -0.003 | -0.003 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit Ratio
| 0 | 0 | 0.833 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 23.634 | 12.991 | 8.095 | 7.585 | 8.704 | 7.415 | 11.369 | 9.024 | 11.401 | 10.455 | 12.098 | 0.67 | 29.867 | 0 |
| General & Administrative Expenses
| 6.916 | 6.806 | 6.931 | 5.392 | 4.482 | 5.516 | 5.327 | 5.746 | 6.252 | 5.487 | 12.894 | 5.598 | 2.815 | 0 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -10.67 | 0 | 0 | 0 |
| SG&A
| 6.916 | 6.806 | 6.931 | 5.392 | 4.482 | 5.516 | 5.327 | 5.746 | 6.252 | 5.487 | 2.224 | 5.598 | 2.815 | 0.094 |
| Other Expenses
| 5.937 | 5.915 | 7.186 | 1.386 | 0.843 | 0.724 | 0.24 | 0.038 | 0.245 | 0.07 | 0.007 | -0.021 | -0.004 | 0.018 |
| Operating Expenses
| 30.55 | 19.798 | 15.026 | 12.977 | 13.186 | 12.932 | 16.696 | 14.771 | 17.652 | 15.942 | 2.224 | 6.267 | 32.682 | 0.094 |
| Operating Income
| -30.578 | -19.82 | -15.029 | -12.977 | -13.186 | -12.932 | -16.696 | -14.771 | -17.652 | -15.942 | -2.224 | -6.267 | -32.682 | -0.094 |
| Operating Income Ratio
| 0 | 0 | -761.419 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 5.898 | 5.915 | 7.186 | 1.386 | 0.843 | 0.724 | 0.24 | 0.038 | 0.245 | 0.07 | 0.002 | -0.021 | -0.004 | 0.018 |
| Income Before Tax
| -24.68 | -13.905 | -7.843 | -11.59 | -12.343 | -12.208 | -16.457 | -14.733 | -17.407 | -15.873 | -2.222 | -6.288 | -32.686 | -0.076 |
| Income Before Tax Ratio
| 0 | 0 | -397.36 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 0.079 | 0.07 | 0.044 | 0.029 | 0.01 | 0.011 | 0.011 | 0.009 | 0.009 | 0.007 | 0.006 | 0 | -0 | -0.055 |
| Net Income
| -24.267 | -13.674 | -7.437 | -9.426 | -10.139 | -12.219 | -16.468 | -14.742 | -17.416 | -15.88 | -2.222 | -6.288 | -32.686 | -0.076 |
| Net Income Ratio
| 0 | 0 | -376.79 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS
| -0.39 | -0.22 | -0.12 | -0.18 | -0.23 | -0.31 | -0.42 | -0.4 | -0.49 | -0.43 | -0.15 | -0.17 | -0.89 | -0.005 |
| EPS Diluted
| -0.39 | -0.22 | -0.12 | -0.18 | -0.23 | -0.31 | -0.42 | -0.4 | -0.49 | -0.43 | -0.15 | -0.17 | -0.89 | -0.005 |
| EBITDA
| -30.55 | -19.798 | -15.026 | -12.973 | -13.183 | -12.928 | -16.696 | -14.767 | -17.652 | -15.94 | -2.224 | -6.265 | -32.682 | -0.094 |
| EBITDA Ratio
| 0 | 0 | -761.252 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |